Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 9/20 | 0.47 |
| ▸ | REN | P00797 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PEPD | P12955 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24339739 | 1.00 | LMNA (0.61) | LMNAHSD17B10CYP2C19RIPK1ACE | |
| SCHEMBL11922857 | 1.00 | LMNA (0.61) | LMNAHSD17B10CYP2C19RIPK1ACE | |
| SCHEMBL2636385 | 0.94 | LMNA (0.68) | LMNAHSD17B10CYP2C19RIPK1ACE | |
| SCHEMBL3189885 | 0.94 | LMNA (0.68) | LMNAHSD17B10CYP2C19RIPK1ACE | |
| SCHEMBL11993551 | 0.94 | LMNA (0.68) | LMNAHSD17B10CYP2C19RIPK1ACE | |
| SCHEMBL19075666 | 0.86 | LMNA (0.53) | LMNAHSD17B10CYP2C19RIPK1ACE | |
| SCHEMBL12788610 | 0.85 | LMNA (0.45) | LMNAHSD17B10CYP2C19RIPK1 | |
| SCHEMBL13662629 | 0.84 | LMNA (0.44) | LMNAHSD17B10CYP2C19RIPK1 | |
| SCHEMBL5520595 | 0.83 | LMNA (0.55) | LMNAHSD17B10CYP2C19ACEREN | |
| SCHEMBL5966063 | 0.82 | FKBP1A (0.57) | LMNAHSD17B10CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220098214-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING FIBROSIS | YALE UNIVERSITY | 2022-03-31 | — | — | US | disclosed |
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-03-18 | — | — | US | disclosed |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-01-31 | — | — | US | disclosed |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| CN-104072486-B | As the connection-1H-benzoglyoxaline of hepatitis C virus inhibitors | SQUIBB BRISTOL MYERS CO. (US) | 2016-04-06 | — | — | CN | disclosed |
| CN-104072486-A | BI-1H-BENZIMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO | 2014-10-01 | — | — | CN | disclosed |
| CN-102177141-B | bis-1H-benzimidazoles as hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO | 2014-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | LMNA 462/4885HSD17B10 2827/4885CYP2C19 565/4885 |
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | LMNA 462/4885HSD17B10 2827/4885CYP2C19 565/4885 |
| US-20190031607-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | LMNA 462/4885HSD17B10 2827/4885CYP2C19 565/4885 |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | LMNA 462/4885HSD17B10 2827/4885CYP2C19 565/4885 |
| US-20220098214-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING FIBROSIS | DUSP5, DUSP4, DUSP6 | LMNA 2987/4885HSD17B10 1520/4885CYP2C19 4862/4885 |
| US-20210078947-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | LMNA 462/4885HSD17B10 2827/4885CYP2C19 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.